Results 21 to 30 of about 624 (180)

TRIMETAZIDINE AND MILDRONATE AS DIRECT ACTION Β2 - ADRENOSENSIBILIZERS (EXPERIMENTAL EVIDENCE)

Российский кардиологический журнал, 2002
Trimetazidine and mildronate as direct action β2 - adrenosensibilizers (experimental evidence).
V. I. Tsirkin, E. N. Sizova, A. D. Podtenev, T. V. Bratchikova, O. V. Anisimova, A. N. Truhin, S. A. Dvoryansky   +6 more
doaj   +1 more source

Mildronate and its Neuroregulatory Mechanisms: Targeting the Mitochondria, Neuroinflammation, and Protein Expression [PDF]

Medicina, 2013
This review for the first time summarizes the data obtained in the neuropharmacological studies of mildronate, a drug previously known as a cardioprotective agent.
Ivars Kalvinsh, Beitnere, Ulrika, Jolanta Pupure, Dzirkale, Zane, Svirskis, Simons, Vija Klusa, Zane Dzirkale, Ulrika Beitnere, Juris Rumaks, Isajevs, Sergejs, Rumaks, Juris, Kalvinsh, Ivars, Pupure, Jolanta, Simons Svirskis, Sergejs Isajevs   +14 more
core   +3 more sources

MILDRONATE POTENTIAL FOR CARDIAC ARRHYTHMIA PREVENTION IN PERIOPERATIVE PERIODcardiac arrhythmias, ischemia, metabolic disturbances, cytoprotectors, antioxidants, operation-related stress, general anesthesia, Mildronate

Кардиоваскулярная терапия и профилактика, 2014
Aim. To assess the effectiveness of Mildronate in the prevention of arrhythmias during the perioperative period of open cholecystectomy under intravenous multicomponent anesthesia.Material and methods.
V. P. Mikhin, N. A. Volkova, S. A. Sumin, P. A. Eremin   +3 more
doaj   +2 more sources

MILDRONATE POTENTIAL FOR CORRECTING COGNITIVE DYSFUNCTION IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION

Российский кардиологический журнал, 2011
The study aimed to assess the effects of long-term and course mildronate therapy (500 mg/d) on cognitive function in elderly patients with arterial hypertension (AH) and cognitive dysfunction.
M. E. Statsenko, S. V. Nedogoda, S. V. Turkina, I. A. Tyshchenko, L. V. Poletaeva, E. V. Chumachok, A. A. Ledyaeva, V. V. Tsoma   +7 more
doaj   +1 more source

Mildronate (meldonium): First, do no harm

, 2020
Meldonium (Mildronate) is used as a cardioprotective drug; however, it has not been officially approved anywhere outside the former Soviet Union (SU). The supposed action mechanism is based on the carnitine (Lcarnitine) lowering effect in muscular and ...
Jargin S.V.
core   +2 more sources

New views of mildronate use for the prevention and correction of impairment of adaptive processes

RUDN Journal of Medicine, 2009
Protective and normalizing mildronate action on the level of non enzyme kation proteins in the neurophils and contents of kateholamins in erythrocytes were revealed on the experimental model of the emotional-pain stress.
L V Logunova
doaj   +1 more source

CYTOPROTECTOR MILDRONATE IN CORRECTING MYOCARDIAL DYSFUNCTION AMONG STABLE ANGINA PATIENTS AFTER CORONARY REVASCULARISATION

Российский кардиологический журнал, 2009
In total, 149 patients, aged 41–75 years, with Functional Class (FC) II-III stable angina, who underwent coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI), were examined.
I. G. Gordeev, E. E. Luchinkina, S. V. Hegay   +2 more
doaj   +1 more source

Mildronate. Chronic fatigue syndrome

Medical alphabet, 2020
Chronic fatigue syndrome (CFS) is a state of constant, impairing quality of life, fatigue, lasting more than 6 months, inexplicable by any of coexisting patient’s pathological conditions. The prevalence of CFS in the world is approximately 2 % of the population (120–140 mln inhabitants of Earth). The etiology of CFS is unknown.
A. V. Filippova, A. P. Pereverzev, E. Yu. Ebzeeva, O. D. Ostroumova   +3 more
openaire   +2 more sources

Endothelial dysfunction in heart failure with normal systolic function, and its correction with a metabolic agent, mildronate

Российский кардиологический журнал, 2005
To assess the influence of a metabolic agent, mildronate, on endothelial function in chronic heart failure (CHF) with normal systolic function, 105 patients with I-IIA Stage, II-III Functional Class (FC) CHF, and normal left ventricular systolic function,
V. P. Geychenko, A. V. Kuryata, O. V. Muzhchil   +2 more
doaj   +1 more source

MILDRONATE THERAPY IN PATIENTS WITH CHRONIC HEART FAILURE, TYPE 2 DIABETES MELLITUS AND AUTONOMOUS CARDIAC NEUROPATHY

Российский кардиологический журнал, 2009
In total, 60 45-70-year-old patients with Functional Class II-III chronic heart failure (CHF) after a myocardial infarction, compensated or sub-compensated Type 2 diabetes mellitus (DM-2), and autonomous cardiac neuropathy were examined.
M. E. Statsenko, S. V. Turkina, S. V. Belenkova   +2 more
doaj   +1 more source